LG Chem, Ltd.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 051910.KS | 011170.KS | 298000.KS | 1326.TW | 014440.KS | BEPL.BO | |
|---|---|---|---|---|---|---|
| Market cap | 19.26T | 2.13T | 131.12B | 380.19B | 91.75B | 27.62B |
| P/E (TTM) | — | — | — | 27.5 | — | 16.6 |
| Forward P/E | — | — | — | 19.8 | — | 19.1 |
| Price/book | — | — | — | 0.7 | — | 2.7 |
| Dividend yield | 0.81% | 2.03% | — | 0.87% | 7.42% | 4.66% |
| 1-year change | −35.84% | −29.61% | −3.60% | +148.92% | +7.27% | −28.11% |
| Today | −0.40% | +2.44% | −7.20% | −6.07% | −0.32% | +0.54% |
The closest companies by business and industry (Chemicals). Prices may be delayed up to 20 min.
Latest news
All 051910.KS news ›Rhythm Pharmaceuticals changes its tune with LG Chem on obesity drug
Rhythm Pharmaceuticals has amended its exclusive license agreement with LG Chem for bivamelagon, an oral small-molecule melanocortin-4 receptor (MC4R) agonist. The changes raise the deal's potential value from $305 million to as much as…
LG Chem Expands Rare Obesity Drug Deal to 1.15 Trillion Won
LG Chem expanded its bivamelagon licensing deal with Rhythm Pharmaceuticals to 1.15 trillion won, with record upfront payments of about 600 billion won. LG Chem (051910) has expanded the value of its licensing deal with U.S.-based Rhythm…
LG Chem Raises Bivamelagon Deal Value with U.S.-Based Rhythm
LG Chem announced on Nov. 3 (on Oct. 2, local time) that it agreed to amend the technology export contract regarding the global development and sales of ‘Vivamelagon’, an oral melanocortin-4 receptor (MC4R) agonist, with Rhythm…
LG Chem Expands Obesity Drug Licensing Deal to $855 Million
Deal Value Grows From $305 Million to $855 Million Company to Receive $350 Million in Additional Upfront Payments Through 2029 Positive Phase 2 Results Clear Path to Phase 3 This Year LG Chem (051910.KS) has expanded the global licensing…
LG Chem boosts Rhythm deal as obesity drug advances toward global phase 3
Rhythm, not LG Chem, will shoulder bigger upfronts as Bivamelagon readies for phase 3 and milestones climb LG Chem(051910) expanded the size of the contract for a rare obesity treatment candidate it out-licensed to Rhythm Pharmaceuticals…
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed payments totaling $350…
LG Chem to sell 2.5 tln-won stake in battery unit to boost shareholder value
SEOUL, Oct. 28 (Yonhap) -- LG Chem Ltd., South Korea's leading chemical company, said Wednesday it will sell 2.5 trillion won (US$1.87 billion) worth of shares in its battery unit to enhance shareholder value. Following the planned sale,…
LG Chem Expands Business into Four Core Growth Engines
Aiming to triple growth by 2030 with eco-friendly, battery, drug, and specialty sectors LG Chem
U.S. Battery Energy Storage Thermal Runaway Detection Market Is Going to Boom |• A123 Systems • LG Chem
The U S Battery Energy Storage Thermal Runaway Detection Market is witnessing evolving industry dynamics driven by technological advancements changing customer requirements and emerging business opportunities In its latest research…
Asimov Announces Adoption of Its AI-Driven Cell Line Development Platform by LG Chem
Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a licensing agreement with South Korea-based LG Chem, a leading global chemical company with a diversified business…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- en.sedaily.com6
- asiae.co.kr3
- en.yna.co.kr2
- biz.chosun.com1
- businesskorea.co.kr1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 27 articles, not a forecast.